| Literature DB >> 35509038 |
Mariusz Flisiński1, Ewa Skalska2, Barbara Mączyńska2, Natalia Butt-Hussaim3, Agnieszka Sobczyńska-Tomaszewska4, Olga Haus5, Jacek Manitius3.
Abstract
BACKGROUND: Gitelman Syndrome (GS) is a hereditary tubulopathy associated with a biallelic inactivating mutations of the SLC12A3 gene encoding the thiazide-sensitive sodium-chloride cotransporter (NCCT). The typical clinical manifestation is a hypokalemic metabolic alkalosis with significant hypomagnesemia, and low urinary calcium excretion. Hypocalciuria is widely believed to be a hallmark of GS that distinguishes it from Barter's syndrome, presenting as hypercalciuria. The pathomechanism of hypocalciuria in GS is not fully elucidated. Up to date, a clinical course of GS with normocalciuria has been reported only in men, while women have a milder course of the disease with typical hypocalciuria, which is believed as the result of sex hormone. Additionally, there is a growing evidence that calcium channels of the distal nephron could be regulated by a variety of hormones, including aldosterone (Aldo). CASEEntities:
Keywords: A case-report; Aldosterone; Gitelman syndrome; Normocalciuria; Tubulopathy; Urinary calcium excretion
Mesh:
Substances:
Year: 2022 PMID: 35509038 PMCID: PMC9069753 DOI: 10.1186/s12882-022-02782-y
Source DB: PubMed Journal: BMC Nephrol ISSN: 1471-2369 Impact factor: 2.585
Fig. 1Algorithm for differential diagnosis of hypokalemia
The results of biochemical tests of serum and blood gas analysis at the baseline
| Laboratory parameter | Patient results | Normal range |
|---|---|---|
| Sodium [mmol/L] | 136.6 | 136–145 |
| Potassium [mmol/L] | 2.4 | 3.5–5.0 |
| Chloride [mmol/L] | 96.6 | 98–110 |
| Calcium [mmol/L] | 2.51 | 2.1–2.55 |
| Magnesium [mmol/L] | 0.55 | 0.85–1.15 |
| Phosphate [mmol/L] | 1.21 | 0.74–1.52 |
| Serum osmolality [mOsmol/kg H2O] | 294 | 285–295 |
| Creatinine concentration [mg/dL] | 0.76 | 0.60–1.10 |
| Glomerular filtration (GFR) according to MDRD [mL/min/1.73m2] | 96.5 | ≥90 |
| Renin in supine position [μU/mL] | 80.7 | 4.2–59.7 |
| Renin in upright position [μU/mL] | 308.6 | 5.3–99.1 |
| Aldosterone in supine position [ng/dL] | 13.6 | 3.7–31.0 |
| Aldosterone in upright position [ng/dL] | 35.7 | 3.7–43.2 |
| PTH [pg/mL] | 26.2 | 18,5-88,0 |
| 25-hydroxyvitamin D3 [ng/mL] | 51.6 | 30–100 |
| Alkaline phosphatase [U/L] | 85 | 46–116 |
| Glucose [mg/dL] | 86 | 70–99 |
| HbA1c [%] | 5.6 | < 5,7% |
| Albumin [g/dL] | 4.3 | 3.5–5.0 |
| Uric acid [mg/dL] | 4.8 | 2.6–6.0 |
| AST [U/l] | 21 | < 34 |
| ALT [U/l] | 34 | < 36 |
| pH | 7.374 | 7.35—7.45 |
| HCO3 concentration [mmol/L] | 33 | 21—27 |
| BE [mmol/L] | 5.9 | −2.3 — + 2.3 |
| pCO2 [mmHg] | 57.8 | 32—45 |
The results of 24-h urine collection at the baseline
| Laboratory parameter | Patient result | Normal range |
|---|---|---|
| Creatinine excretion [mmol/day] | 10.79 | 6.54–13.88 |
| Sodium excretion [mmol/day] | 262.7 | 40–220 |
| Potassium excretion [mmol/day] | 506.2 | 25–125 |
| Magnesium excretion [mmol/day] | 11.7 | 3.0–5.0 |
| Calcium excretion [mmol/day] | 4.32 | 2.50–8.00 |
| Chloride excretion [mmol/day] | 0.45 | 0.11–0.25 |
| Potassium fractional excretion [%] | 79.6 | < 6.5% (if hypokalemia) |
| Sodium fractional excretion [%] | 1.2 | 0–1 |
| Magnesium fractional excretion [%] | 12.1 | 2–4 |
| Calcium fractional excretion [%] | 0.12 | 0.01–0.25 |
| Chloride fractional excretion [%] | 3.4 | < 0.5 |
The results of biochemical tests of spot urine and serum at the baseline and the control visit
| Laboratory parameter | Patient result at the baseline | Patient result at the control | Normal range |
|---|---|---|---|
| pH | 8 | 7.5 | 5.0–6.9 |
| Urine-specific gravity | 1.008 | 1.016 | > 1.023 |
| Protein | negative | negative | negative |
| Albumin to creatinine ratio (ACR) [mg/mmol] | 0.752 | Not done | < 3 |
| Protein to creatinine ratio (PCR) [mg/mmol] | 14.2 | 21.3 | < 15 |
| Glucose [mg/dL] | absent | absent | (−) |
| Urine osmolality [mOsmol/kg H2O] | 454 | Not done | 50–1400 |
| Sodium concentration [mmol/L] | 65 | 41.5 | 25–150 |
| Potassium concentration [mmol/L] | 121.8 | Not done | 25–100 |
| Chloride concentration [mmol/L] | 165 | 306 | 20–40 |
| Magnesium concentration [mmol/L] | 3.29 | 6.30 | 0.4–6.67 |
| Calcium to creatinine ratio (Ca/Cr) [mmol/mmol] | 0.39 | 0.24 | 0.20–0.57 |
| Aldosterone in supine position | 35.7 | 52.0 | 3.7–43.2 |
| Creatinine concentration [mg/dL] | 0.67 | 0.57 | 0.60–1.10 |
| Glomerular filtration rate (GFR) according to CKD-EPI [mL/min/1.73m2] | 120 | 124 | ≥90 |
| Sodium [mmol/L] | 139.2 | 140.9 | 136–145 |
| Potassium [mmol/L] | 3.9 | 3.9 | 3.5–5.0 |
| Chloride [mmol/L] | 98.8 | 104.9 | 98–110 |
| Calcium [mmol/L] | 2.42 | 2.42 | 2.1–2.55 |
| Magnesium [mmol/L] | 0.53 | 0.62 | 0.85–1.15 |
Fig. 2Identification of the SLC12A3 mutations using Sanger sequencing. *Missense mutation c.1247G > C leads to p.Cys416Ser (A), mutation c.2186G > T leads to p.Gly729Val (B). The reference sequences were: NM_000339.2 and NP_000330.2